Latest Breaking News On - Lymphoma division - Page 1 : comparemela.com

Goy Gives Insights Into the Future Management of Lymphoma and Multiple Myeloma

Dr Goy discusses the impact of CAR T-cell therapy on the lymphoma and multiple myeloma treatment paradigms and his anticipations for the future of hematologic oncology.

New jerseyUnited statesGeorgetown universityDistrict of columbiaHackensack university medical centerAshling wahnerLydia pfundAndreh goyHackensack meridian school of medicineLymphoma divisionOncology care transformation servicesJohn theurer cancer centerLive on airLydia pfund chairHackensack meridian schoolOnclive on air

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Andre goyLydia pfundHackensack meridian health oncology care transformation servicesHackensack meridian school of medicineJohn theurer cancer centerLymphoma divisionGeorgetown universityHackensack university medical centerLydia pfund chairHackensack meridian school

Dr Goy on the Rationale for Launching the ZUMA-18 Trial in Relapsed/Refractory MCL

Andre Goy, MD, discusses the evaluation of brexu-cel in the ZUMA-2 and expanded access ZUMA-18 trials in relapsed/refractory mantle cell lymphoma.

United statesAndre goyHackensack meridian health oncology care transformation servicesJohn theurer cancer centerLymphoma divisionHackensack university medical centerJohn theurer cancer centerHackensack university medical centerOnclive tvMantle cell lymphoma

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite s Tecartus® in Patients With Aggressive Blood Cancers

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite s Tecartus® in Patients With Aggressive Blood Cancers
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesFoster cityAndre goySwetha kambhampatiFrank neumannSanta monicaEvandro bezerraGilead sciences incHackensack university medical centerOhio state university comprehensive cancer centerLymphoma divisionGilead company nasdaqGilead companyMarrow transplant researchDivision of lymphomaProduct service

Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL

Andre Goy, MD, discusses outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma enrolled in the phase 2 ZUMA-2 trial and the expanded access ZUMA-18 study.

Andre goyJohn theurer cancer centerHackensack meridian health oncology care transformation servicesHackensack university medical centerLymphoma divisionAsh annual meeting and expositionOnclive tvMantle cell lymphomaMash 2023